Andrew R. Allen

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boulder, CO
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Andrew R. Allen

Form 4 holding PRESIDENT AND CEO, Director

Gritstone bio, Inc.

Security class
Common Stock
Shares / value
1,124,275
Estimated value
$841,295
Report date
24 Jun 2024
Price
$0.7483
Ownership
Indirect
Form 4 holding PRESIDENT AND CEO, Director

Gritstone bio, Inc.

Security class
Common Stock
Shares / value
985,360
Estimated value
$737,345
Report date
24 Jun 2024
Price
$0.7483
Ownership
Direct
Form 4 holding PRESIDENT AND CEO, Director

Gritstone bio, Inc.

Security class
Common Stock
Shares / value
325,000
Estimated value
$243,198
Report date
24 Jun 2024
Price
$0.7483
Ownership
Allen 2024 Gift Trust
Form 4 holding Director

Epizyme, Inc.

Security class
Common Stock, par value $0.0001
Shares / value
20,560
Estimated value
$28,990
Report date
11 Jun 2021
Price
$1.41
Ownership
Direct
Form 4 holding Director

Adaptimmune Therapeutics PLC

Security class
Option to purchase Ordinary Shares
Shares / value
660,000
Estimated value
Report date
01 Jul 2024
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding PRESIDENT AND CEO, Director

Gritstone bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
615,000
Estimated value
Report date
15 May 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Epizyme, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
40,559
Estimated value
Report date
11 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Sierra Oncology, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
01 Jul 2022
Price
$55.00
Ownership
Direct
Form 4 holding Director, 10%+ Owner

Sierra Oncology, Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
01 Jul 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

TCR2 THERAPEUTICS INC.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
01 Jun 2023
Price
$0.7400
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Andrew R. Allen

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .